pasti melantun balik... mungkin kerajaan baru akan bayar pampasan untuk stok lebihan akibat kelalaian dan fokus kpd pru awal (Kerajaan Lama) dan menjejaskan suntikan booster pertama dan kedua untuk semua rakyat..
Usah bimbang.. Menteri ekonomi, rafizi, chartered accountant.. dia faham punya.......selamatkan pharma, segala pujian milik kerajaan baru... kerajaan lama dikutuk habis-habisan
"Hey grandson! Keep this shiny rock and maybe it'll be worth something one day". After 1000 years later someone takes the grandson words way too literal and cut it in half.
Ramai scammers menyeru pihak lain jualkan semua syer supaya mereka dapat syer harga lelong... Hakikatnya, tiada seorang pun berani short syer pharma sampai sekarang. Betapa power pharma :)
Our colleague, Trevor777 fiery battle with the one calling herself (actual profession pasar malam pisang goreng seller) GodofGamber (remember?) and also witnessed by Mr KfLiau and Cipta....they are still reading these.
KUALA LUMPUR (March 2): The Armed Forces Fund Board (LTAT) is understood to be taking Boustead Holdings Bhd private.
The armed forces pension fund holds a 59.4% stake in the group.
It is not currently known how much LTAT will be offering to shareholders to privatise the group.
Trading of Boustead's securities is suspended from 2.30pm to 5pm on Thursday pending a material announcement, according to a filing on Bursa Malaysia.
The conglomerate sank into the red in the fourth quarter ended Dec 31, 2022 (4QFY2022), posting a net loss of RM402.3 million after its 52%-owned subsidiary Pharmaniaga Bhd reported a whopping RM552.3 million impairment provision for the drug maker's unsold Covid-19 vaccine stock.
Boustead incurred a loss per share of 19.85 sen, in contrast to earnings per share of 3.88 sen, or RM78.6 million, in 4QFY2021. This was despite a 25% growth in quarterly revenue to RM3.69 billion from RM2.96 billion, Boustead's Bursa Malaysia filing showed.
Group chief executive officer Izaddeen Daud, who took over the post in December last year, said the writedown was “indeed deeply concerning”.
“Nevertheless, we are confident that Pharmaniaga remains a going concern and is well poised to tap on the strong prospects of the pharmaceutical sector, domestically and regionally.
“We are supporting the management team to ensure a robust regularisation plan is in place to strengthen the company’s balance sheet and progressively work towards the upliftment of the PN17 (Practice Note 17) status,” he added.
On Thursday, the group had redesignated director Datuk Ahmad Nazim Abd Rahman as its non-independent and non-executive chairman.
Ahmad Nazim, 47, is also the chief executive officer of LTAT, which holds a 54.9% stake in the group.
According to a bourse filing, Ahmad Nazim has “more than two decades of corporate, investment and restructuring experience across multiple geographies and industries”.
The day before, Boustead redesignated its group finance director Fahmy Ismail as its group chief financial officer.
Fahmy is currently serving as acting chief executive officer of Boustead Plantations Bhd.
UOB Malaysia is understood to be advising LTAT on the privatisation exercise.
At noon break on Thursday, Boustead was up three sen or 4.8% to 65.5 sen, for a market capitalisation of RM1.32 billion.
Read also: Boustead names LTAT CEO Ahmad Nazim as chairman
Probably a strategy to use the provision as an excuse to buyback all shares cheaply via privatisation... What is next after boustead? Pharma pulak hahaha
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
DickyMe
14,892 posts
Posted by DickyMe > 2023-03-02 12:24 | Report Abuse
Gov akan tolong tutup syarikat "toll"